Opes Wealth Management LLC Acquires 4,640 Shares of Johnson & Johnson $JNJ

Opes Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 61.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 12,169 shares of the company’s stock after buying an additional 4,640 shares during the period. Opes Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,859,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Apexium Financial LP increased its holdings in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB increased its holdings in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC increased its holdings in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after buying an additional 4,816 shares during the last quarter. Finally, Klingman & Associates LLC boosted its stake in shares of Johnson & Johnson by 13.4% during the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after purchasing an additional 2,005 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $190.38 on Friday. The company has a 50 day moving average price of $182.26 and a 200-day moving average price of $166.13. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The stock has a market capitalization of $458.69 billion, a PE ratio of 18.38, a PEG ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. UBS Group boosted their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.